McKesson Corporation (LON: 0JZU)
London
· Delayed Price · Currency is GBP · Price in USD| Market Cap | 58.53B |
| Revenue (ttm) | 246.35B |
| Net Income (ttm) | 1.89B |
| Shares Out | n/a |
| EPS (ttm) | 14.42 |
| PE Ratio | 30.94 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Dec 2, 2024 |
| Volume | 279 |
| Open | 576.60 |
| Previous Close | 572.40 |
| Day's Range | 569.47 - 582.95 |
| 52-Week Range | 335.28 - 582.95 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 6, 2025 |
About McKesson
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty ... [Read more]
Financial Performance
In 2023, McKesson's revenue was $308.95 billion, an increase of 11.65% compared to the previous year's $276.71 billion. Earnings were $3.00 billion, a decrease of -15.67%.
Financial numbers in USD Financial StatementsNews
Gordon Reid's Top Picks: Booking Holdings, McKesson Corp. and Uber
Gordon Reid, president of Goodreid Investment Counsel, discusses his top picks: Booking Holdings, McKesson Corp. and Uber.
Gordon Reid's Top Picks: Broadcom, Booking Holdings, McKesson Corp. and Uber
Gordon Reid, president of Goodreid Investment Counsel, discusses his top picks: Broadcom, Booking Holdings, McKesson Corp. and Uber
Peering Into McKesson's Recent Short Interest
McKesson's (NYSE: MCK) short percent of float has fallen 9.26% since its last report. The company recently reported that it has 1.91 million shares sold short , which is 1.47% of all regular shares t...
Here's How Much $1000 Invested In McKesson 15 Years Ago Would Be Worth Today
McKesson (NYSE: MCK) has outperformed the market over the past 15 years by 3.86% on an annualized basis producing an average annual return of 15.88%. Currently, McKesson has a market capitalization o...
If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today
McKesson (NYSE: MCK) has outperformed the market over the past 20 years by 7.22% on an annualized basis producing an average annual return of 15.66%. Currently, McKesson has a market capitalization o...
Insider Sell: Leann Smith Sells 579 Shares of McKesson Corp (MCK)
Insider Sell: Leann Smith Sells 579 Shares of McKesson Corp (MCK)
12 High-Yield Dividend Aristocrats To Weather The Coming 2025 Storm In Style
The S&P is up almost 28% in 2024, and many investors worry about a melt-up followed by a sharp correction like in 2022 or 2018. A 2025 market correction is likely, but low-volatility, high-yield Divid...
Brian Madden's Past Pick: Franco Nevada, McKesson and Uber
Brian Madden, CIO of First Avenue Investment Counsel, discusses his past picks: Franco Nevada, McKesson and Uber.
McKesson Corporation (MCK) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)
McKesson Corporation (NYSE:MCK) Annual Evercore ISI HealthCONx Healthcare Conference December 4, 2024 8:20 AM ETCompany ParticipantsBritt Vitalone -...
Jim Cramer looks back at the S&P 500s top performing stocks in November
'Mad Money' host Jim Cramer looks at November's top performing S&P 500 stocks and which could continue to perform into the new year.
Jim Cramer lists 10 stocks likely to perform well in December
CNBC's Jim Cramer listed ten stocks he thinks will do well in December. Cramer said winners from November usually continue to perform during the last month of the year.
Insider Decision: Steven H Collis Offloads $12.20M Worth Of Cencora Stock
Disclosed on November 26, Steven H Collis , Executive Chairman at Cencora (NYSE: COR), executed a substantial insider sell as per the latest SEC filing. What Happened: Collis opted to sell 50,000 sha...
McKesson: Q2 FY2025 Earnings, Growing U.S. Oncology Network
I reiterate a 'Strong Buy' on McKesson, driven by growth from GLP-1 medications and a robust oncology network business, with a fair value of $696 per share. McKesson's acquisition of a 70% interest in...
These Analysts Boost Their Forecasts On McKesson Following Upbeat Earnings
McKesson MCK reported better-than-expected second-quarter financial results on Wednesday.
McKesson Corporation (MCK) Q2 2025 Earnings Call Transcript
McKesson Corporation (MCK) Q2 2025 Earnings Call Transcript
McKesson raises annual profit forecast on strength in its U.S. pharma segment
Drug distributor McKesson Corp raised its annual profit forecast on Wednesday, driven by increased sales in its U.S. pharmaceuticals segment on robust demand for specialty and branded drugs.
McKesson Corporation Reports Fiscal 2025 Second Quarter Results and Raises Full Year Adjusted EPS Guidance
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2025 second quarter financial results. Results can be accessed on McKesson's Investor Relations website at inve...
McKesson Corporation Declares Quarterly Dividend
IRVING, Texas--(BUSINESS WIRE)--The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 71 cents per share of common stock. The dividend will be payable on J...
McKesson Corporation: A Defensive Healthcare Value Stock Without A Patent Cliff
Healthcare is a great defensive sector that has lower amounts of cyclicality than others that depend on the booming economy. With the stock currently down -21.44% off of its all-time high, the stock i...
InspiroGene by McKesson Unveils First-of-its-Kind Report on State of the Cell and Gene Therapy Landscape, Revealing Unparalleled Optimism Amidst Complex Challenges
IRVING, Texas--(BUSINESS WIRE)--InspiroGene™ by McKesson today announced the publication of its inaugural 2024 Cell and Gene Therapy Report: Advancing the Future of Medicine.
McKesson Launches InspiroGene, a Dedicated Business to Guide and Support the Commercialization of Cell and Gene Therapies
IRVING, Texas--(BUSINESS WIRE)--McKesson launches InspiroGene by McKesson, a dedicated business focused solely on supporting the commercialization of cell and gene therapies.
Stock Of The Day: Has McKesson Found Its Bottom And Will It Bounce Back?
The best traders traders focus on key price levels and stock momentum, understanding that oversold stocks at support often experience a rally.
McKesson Corporation Announces Second Quarter Fiscal 2025 Earnings Release Date
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) will release its second quarter fiscal 2025 financial results after market close on Wednesday, November 6, 2024. The company will host ...
McKesson - Meet The New Dividend Stock On My Watchlist
McKesson's recent sell-off offers a compelling opportunity, driven by its strong position in healthcare distribution and growing focus on AI and technology for sustainable growth. The company boasts s...
McKesson, News Corporation And 2 Other Stocks Executives Are Selling
The Nasdaq 100 closed lower by over 500 points during Friday's session. Investors, meanwhile, focused on some notable insider trades.